These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 32033764)

  • 41. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Lee C; Kim J; Jung Y
    Cells; 2019 Oct; 8(10):. PubMed ID: 31619023
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Noninvasive estimation of disease activity and liver fibrosis in nonalcoholic fatty liver disease using anthropometric and biochemical characteristics, including insulin, insulin resistance, and 13C-methionine breath test.
    Korkmaz H; Unler GK; Gokturk HS; Schmidt WE; Kebapcilar L
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1137-43. PubMed ID: 26049707
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016.
    Kaswala DH; Lai M; Afdhal NH
    Dig Dis Sci; 2016 May; 61(5):1356-64. PubMed ID: 27017224
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children.
    Kleiner DE; Makhlouf HR
    Clin Liver Dis; 2016 May; 20(2):293-312. PubMed ID: 27063270
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapies in non-alcoholic steatohepatitis (NASH).
    Oseini AM; Sanyal AJ
    Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pathologic Diagnosis of Nonalcoholic Fatty Liver Disease.
    Lai J; Wang HL; Zhang X; Wang H; Liu X
    Arch Pathol Lab Med; 2022 Aug; 146(8):940-946. PubMed ID: 34871361
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nonalcoholic Steatohepatitis.
    Suzuki A; Diehl AM
    Annu Rev Med; 2017 Jan; 68():85-98. PubMed ID: 27732787
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Similarities and Differences Between Nonalcoholic Steatohepatitis and Other Causes of Cirrhosis.
    Samji NS; Heda R; Kovalic AJ; Satapathy SK
    Gastroenterol Clin North Am; 2020 Mar; 49(1):151-164. PubMed ID: 32033761
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
    Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).
    Drescher HK; Weiskirchen S; Weiskirchen R
    Cells; 2019 Aug; 8(8):. PubMed ID: 31394730
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis.
    Kuchay MS; Misra A
    Diabetes Metab Syndr; 2022 Mar; 16(3):102446. PubMed ID: 35259705
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nonalcoholic fatty liver disease: a systematic review.
    Rinella ME
    JAMA; 2015 Jun; 313(22):2263-73. PubMed ID: 26057287
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View.
    Lindenmeyer CC; McCullough AJ
    Clin Liver Dis; 2018 Feb; 22(1):11-21. PubMed ID: 29128051
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease.
    Pennisi G; Celsa C; Giammanco A; Spatola F; Petta S
    Curr Pharm Des; 2020; 26(32):3928-3938. PubMed ID: 32436818
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A comprehensive review of noninvasive liver fibrosis tests in pediatric nonalcoholic Fatty liver disease.
    Mansoor S; Collyer E; Alkhouri N
    Curr Gastroenterol Rep; 2015 Jun; 17(6):23. PubMed ID: 26031832
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [NASH: a less known but severe complication of diabetes].
    Gariani K; Jornayvaz FR
    Rev Med Suisse; 2020 Jun; 16(697):1197-1199. PubMed ID: 32520458
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
    Brunt EM; Kleiner DE; Wilson LA; Sanyal AJ; Neuschwander-Tetri BA;
    Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nonalcoholic fatty liver disease: different classifications concordance and relationship between degrees of morphological features and spectrum of the disease.
    Monteiro JM; Monteiro GM; Caroli-Bottino A; Pannain VL
    Anal Cell Pathol (Amst); 2014; 2014():526979. PubMed ID: 25763333
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease.
    Bedossa P; Patel K
    Gastroenterology; 2016 Jun; 150(8):1811-1822.e4. PubMed ID: 27003601
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?
    Alkhouri N; Feldstein AE
    Metabolism; 2016 Aug; 65(8):1087-95. PubMed ID: 26972222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.